Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI
NCT: NCT03297125 · ACTIVE_NOT_RECRUITING
Brief Summary
The purpose of this prospective, nonrandomized controlled phase IV study is to compare standard and advanced MRI for their ability to predict response to Optune therapy.
Frequently Asked Questions
What is Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI?
Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI is a clinical trial registered under NCT03297125. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT03297125?
The current status of NCT03297125 (Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI) is: ACTIVE_NOT_RECRUITING.
When did Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI start?
Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI started on 2017-12-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.